Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor ...

Congruence Therapeutics has completed a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.

An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...

The streamlined framework is part of the UK Government’s plans to ensure the life sciences sector reaches its full potential.

Quintessence's technology is designed to simplify the bio-separation process in CGT manufacturing while reducing production costs.

The FDA has issued a CRL to Aldeyra Therapeutics for its new drug application (NDA) of reproxalap to treat dry eye disease.

R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in CKD ...

In a recent article, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T cells directly within the body.

The court ruling reverses several changes by the CDC’s vaccine panel to childhood immunisation recommendations.

Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six pipeline TCE therapies.

Peter Fassler, Director Market Access at Gilead Sciences, highlighted the challenges facing the Netherlands and the rest of Europe in ensuring access to innovation therapies, at the Advanced Therapies ...

Sentynl Therapeutics has signed an agreement with PRG S&T to license Progerinin, an investigational molecule intended to ...